He circumstance with the individuals. We aimed to observe the efficacy, security, and toxicity in the IAC regimen in relapse/refractory AML and to discover which is the greater regimen. Benefits Forty-two individuals were enrolled inside the clinical trial, having a median age of 36 yearsIAC group, 22 cases and handle groups, 20 instances The objective response price was 71.4 in the IAC group and 40.0 in . the control groupP0.062 the total remissionCRrate was 66.7 inside the IAC group and 40.0 ; within the handle groupP0.121 The median follow- up time of surviving individuals was ten.5range:1.7. 32.8months; the median general survivalOSwas 14.1range: 0.6-49.1months in the IAC group and 9.9range: two.0- 53.8months within the handle groupP0.305 The 1- year OS was 54.595 CI . 33.7-75.3in the IAC group and 48.2 95 CI 25.9-70.5in the manage groupP0.305 , with no considerable distinction between these two regimens. The principle hematologic adverse eventsAEs were anemia, thrombocytopenia, and neutropenia. The incidence of grade 3-4 hematologic AEs within the two groups was 10022/22in the IAC group and 9519/20in the manage group. The median time of neutropenia immediately after chemotherapy within the IAC group and handle group was 20IQR: 8-30and 14IQR: 550days, respectivelyP0.023 The CR price of the early relapserelapse within 12 monthsgroup . was 46.7 and that from the late relapserelapse after 12 monthsgroup was 72.7P0.17 The median . OS time of early recurrence was 9.9range:1.7-53.8months, and that of late recurrence individuals was 19.3 range: 0.6-40.8monthsP0.420 with no considerable differences involving the two groups. The 1-year , OS prices have been 45.three 95 CI 27.2-63.3and 66.7 95 CI 40.0-93.4 respectivelyP , 0.Cadherin-11 Protein supplier 420 Survival evaluation showed that the 1- year OS rates of the hematopoietic stem cell transplantation . group and non- hematopoietic stem cell transplantation group have been 87.5 95 CI 71.two – 100and six.three 95 CI 5.Transthyretin/TTR Protein custom synthesis 7 – 18.3 respectively. The OS rate with the hematopoietic stem cell transplantation , group was substantially greater than that on the non- hematopoietic stem cell transplantation groupP 0.001 Conclusion The IAC regimen is usually a well- tolerated and powerful regimen in relapsed/refractory . AML; this regimen had similar efficacy and safety with the regimen chosen based on the doctor’s practical experience for treating relapsed/refractory AML. For relapsed/refractory patients with AML, allogeneic hematopoietic stem cell transplantation need to be attempted as soon as possible to achieve long- term survival. Important words Leukemia, myeloid, acute; Refractory; Relapsed; Antineoplastic combined chemotherapy protocols Fund system National Key Research and Development Plan of China2021YFC2500300 ; National Organic Science Foundation of China82141122 Haihe Laboratory of Cell Ecosystem ; HH22KYZX0039 CAMS Innovation Fund for Health-related Sciences2020- I2M- C T- A- 019 Tianjin ; ; Municipal Science and Technologies Commission Grant21ZXGWSY00030 Trial Registration ClinacalTrial.PMID:24189672 gov, NCT02937662 DOI ten.3760/cma.j.issn.0253-2727.2022.04.AML CR4 1-35 CR CTX AML 28577-9 CR CTX MAC + Ara-C +CTX AML MAC 10 CTX IACCR AML 50 / AML CTX P450 DNA 51990 Brown CTX2022 four 43Chin J HematolApril 2022Vol. 43No.891. AML AML AML 1 CR 12 AML 1 CR 12 IIT2016006-EC-1CR PR NR CR 5 1.009/L PLT100109/L PR 525 50 CR NR ORR CR PR four. NCI NCI CTC AE four.0 five. 2021 10 11 OS 10.5 1.732.8 6. SPSS 26.0 t Mann-Whitney U 2 two Fisher Log-ra.